Superantigen Conjugate for Solid Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly those using chimeric antigen receptors (CARs), face challenges in effectively targeting and managing solid tumors, with existing therapies showing limited efficacy compared to their success in treating hematological malignancies.
Innovation Solution
A method involving the use of a superantigen conjugate, where a superantigen like Staphylococcal enterotoxin SEA/E-120 is covalently linked to a targeting moiety that binds to cancer antigens, combined with immune cells expressing chimeric antigen receptors (CARs) or T-cell receptors like TRBV7-9, to enhance targeted immune responses against cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CAR therapies are used to treat solid tumors, then immune cell activation is enhanced, but treatment efficacy is limited compared to hematological malignancies
Solution Approach 1:
The patent combines a superantigen (SEA/E-120) with a targeting moiety (antibody or scFv) to create a conjugate that merges two functional elements: the superantigen's ability to strongly activate T-cells and the targeting moiety's ability to specifically bind cancer antigens on solid tumors. This merged construct addresses the limitation of CAR therapies by providing both targeted delivery and potent immune activation in a single agent.
Solution Approach 2:
The superantigen conjugate acts as an intermediary that bridges the gap between the immune system and solid tumor cells. The targeting moiety directs the conjugate to cancer cells, while the superantigen component mediates strong T-cell activation upon binding to T-cell receptors, thereby enhancing the immune response against solid tumors that are otherwise resistant to conventional CAR therapies.
2Reliability
If superantigen conjugate is combined with immune cells, then targeted immune response is enhanced, but treatment complexity increases
Solution Approach 1:
The patent merges the targeting function and immune activation function into a single superantigen conjugate molecule, eliminating the need for separate CAR-modified cells and superantigen administration. This consolidation simplifies the treatment protocol while maintaining enhanced immune response effectiveness.
Solution Approach 2:
The superantigen conjugate performs multiple functions simultaneously: it targets cancer cells through the targeting moiety, activates T-cells through the superantigen component, and can be administered systemically without requiring complex cell modification procedures. This multi-functionality reduces treatment complexity compared to traditional CAR cell therapy approaches.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the immune response against cancer cells by specifically targeting cancer antigens, potentially improving treatment outcomes for both hematological and solid tumors by increasing the effectiveness of immune cell activation and tumor cell killing.
Implementation Method 1
a superantigen conjugate comprising a superantigen (e.g., engineered Staphylococcal enterotoxin superantigen SEA/E-120) covalently linked to a targeting moiety that binds a cancer antigen
Implementation Method 2
T-cell receptors that bind to the superantigen (e.g., T-cell receptors comprising T-cell receptor β variable 7-9 (TRBV7-9))
Data Source
AI summary
The invention provides methods or compositions for treating cancer using an immune cell, e.g, a T-cell, e.g., a CAR T-cell, optionally in combination with a superantigen conjugate. The invention also provides methods for making immune cells, e.g, T-cells, e.g, CAR T-cells, for use in the treatment of cancer.